Bayer China


The Pharmaceuticals Division focuses on prescription drugs for the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. With its innovative pharmaceutical products, Bayer seeks to achieve a significant therapeutic benefit for patients while at the same time satisfying the growing requirements of physicians and health insurers. The Pharmaceuticals division in China is headquartered in Beijing with facilities in Beijing and Guangzhou.


Bayer constructed a pharmaceutical production and packaging facility in Beijing from 1995 to 1997, manufacturing solid and semisolid products. To meet the growing needs of the Chinese market, the company invested significantly in the extension of the company’s Beijing site. The site increased its production capacity several times following the extension and was equipped with state-of-the-art technology. In 2011, the Beijing site received the “Good Manufacturing Practice” certification from the Beijing Drug Administration Bureau.


In anticipation of increasing product demand in China, Bayer invested EUR 100 million to significantly increase the production capacity of its Beijing plant. The capacity extension is designed to ensure a reliable supply of high-quality products to meet the Chinese market’s demand for pharmaceutical products, including the company’s cardiovascular and anti-diabetes products. The extension includes improved logistics for fully automated material handling, analytical laboratories, and high-speed packaging lines.


At the same time, Bayer is forming long-term strategic alliances with well-known academic institutes worldwide to drive fundamental research and explore the frontiers of drug discovery. In China, Bayer is strengthening the partnerships and strategic alliances with leading Chinese academic institutes such as Tsinghua University, Peking University and the Shanghai Institute of Organic Chemistry, to accelerate the translation of fundamental research into clinical treatment and improve China’s pharmaceutical innovation and R&D capabilities. In March 2018, Bayer celebrated its ten years of partnership with Tsinghua University and the two sides extended their strategic partnership to extend the innovative drug discovery alliance for another three years.


Bayer was one of the earliest companies to focus on county-level medical service capabilities in China and continues to invest in this area. Over the past ten years, over 45,000 physicians and hospital executives across 26 provinces have been trained under the “Go West” project. In 2018, the “Go West” project officially entered the third five-year period. In the next five years, the project will be extended to 31 provinces, cities, and regions around the country to increase the coverage outside the central and western regions.


The Pharmaceuticals Division’s Radiology business is a world-renowneddiagnostic imaging solutions provider. In the field of Radiology, Bayer provides solution with imaging contrast media, injection devices and informatics in China. Bayer is seen as the leading expert bringing Chinese radiologists and society to the best science through robust education programs. Supported by the legacy Ultravist in CT modality and Madred injectors, Bayer is also seen as the innovation leader in MR portfolio by Gadovist with whole body indication and liver specific Primovist.